Table 2

Subject Characteristics Prior to Treatment

Demographics

McGill


All Subjects

Age

% male

I-a

I-b

I-a+b

II

III


Celliant™

57.7 ± 11.8

70%

1.2 ± 0.8

0.6 ± 0.7

1.9 ± 1.5

4.7 ± 2.4

2.6 ± 1.0


Control

61.6 ± 11.8

68%

1.3 ± 0.7

1.1 ± 1.0

2.4 ± 1.6

5.4 ± 2.8

3.1 ± 1.1


DPN group


Celliant™

63.0 ± 7.7

85%

1.2 ± 0.9

0.6 ± 0.7

1.9 ± 1.5

5.1 ± 2.6

2.7 ± 1.1


Control

63.9 ± 11.0

77%

1.4 ± 0.7

1.2 ± 1.1

2.5 ± 1.7

5.2 ± 2.9

2.9 ± 0.9


Non-DPN group


Celliant™

52.7 ± 13.1

57%

1.2 ± 0.8

0.6 ± 0.8

1.9 ± 1.5

4.4 ± 2.3

2.4 ± 0.9


Control

59.5 ± 12.3

60%

1.3 ± 0.8

1.1 ± 1.0

2.3 ± 1.6

5.6 ± 2.8

3.3 ± 1.2


Brief Pain Inventory


All Subjects

Pain Severity

Pain Interference

VAS

SF-36: Bodily Pain


Celliant™

4.2 ± 2.4

5.8 ± 2.4

37.8 ± 8.1

4.2 ± 2.4


Control

5.5 ± 2.6

6.4 ± 1.8

34.6 ± 7.8

5.5 ± 2.6


DPN group


Celliant™

4.9 ± 2.0

4.7 ± 2.5

5.9 ± 2.4

34.2 ± 7.4


Control

5.1 ± 2.3

5.5 ± 2.9

6.1 ± 1.9

36.1 ± 7.5


Non-DPN group


Celliant™

3.9 ± 1.9*

3.8 ± 2.3*

5.8 ± 2.5

40.8 ± 7.7


Control

5.3 ± 1.6*

5.6 ± 2.3*

6.6 ± 1.8

33.3 ± 8.1


*denotes significant (p < 0.05) differences between Celliant™ and Control subjects.

York and Gordon BMC Complementary and Alternative Medicine 2009 9:10   doi:10.1186/1472-6882-9-10

Open Data